

S5 Table. Cost (CHF) per patient and cost-effectiveness results in genotype 4

Indication Parameter	Intervention	Comparator 1		Comparator 2	
	SOF+PaR 12 wks	PaR 48 wks	Δ	PbR 48 wks	Δ
Genotype 4 TN					
Drug costs	63,734	20,481	43,253	20,931	42,803
AE costs	15	0	15	0	15
Monitoring costs	3,286	2,797	489	2,797	489
Total treatment costs	67,035	23,278	43,757	23,728	43,307
Health state costs	12,050	21,633	-9,583	21,628	-9,578
Total costs	79,085	44,911	34,174	45,356	33,729
QALYs per patient*	14.1	13.2	0.9	13.2	0.9

AE, adverse event; IE, interferon eligible; II, interferon ineligible; NT, no treatment; PaR, pegylated interferon 2a+ribavirin; PbR, pegylated interferon 2b+ribavirin; QALY, quality-adjusted life year; SOF, sofosbuvir; TE, treatment-experienced; TN, treatment-naïve

* values are rounded to one decimal place